A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Status: Recruiting
Location: See all (16) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
• Received prior standard therapy appropriate for tumor type and stage
• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function
Locations
United States
California
UC Irvine/Chao Family Comprehensive Cancer Center
RECRUITING
Orange
UCLA
RECRUITING
Santa Monica
Florida
Moffitt Cancer Center
RECRUITING
Tampa
Massachusetts
Dana Farber Cancer Institute
RECRUITING
Boston
Maryland
Johns Hopkins University
RECRUITING
Baltimore
New York
Columbia University
RECRUITING
New York
Memorial Sloan-Kettering Cancer Center
RECRUITING
New York
Perlmutter Cancer Center at NYU Langone Health
RECRUITING
New York
Ohio
Christ Hospital Cancer Center
RECRUITING
Cincinnati
Tennessee
Sarah Cannon Research Institute
RECRUITING
Nashville
Texas
University of Texas at Austin
RECRUITING
Austin
Mary Crowley Cancer Research
RECRUITING
Dallas
The University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Next Oncology
RECRUITING
San Antonio
Utah
Huntsman Cancer Institute
RECRUITING
Salt Lake City
Virginia
Next Oncology Virginia
RECRUITING
Fairfax
Contact Information
Primary
Revolution Medicines, Inc.
medinfo@revmed.com
1-844-273-8633
Time Frame
Start Date: 2022-05-31
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 614
Treatments
Experimental: Experimental: RMC-6236
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations.~Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified).~RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Related Therapeutic Areas
Sponsors
Leads: Revolution Medicines, Inc.